VYNE Therapeutics Inc.
News
VYNE Therapeutics to Participate in September Investor Conferences
Globe Newswire BRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ( VYNE or the Company ), a clinical-stage biopharmaceutical company focused on developing...\n more…
VYNE Therapeutics (NASDAQ:VYNE) versus Aravive (NASDAQ:ARAV) Head-To-Head Analysis
Ticker Report VYNE Therapeutics (NASDAQ:VYNE - Get Free Report) and Aravive (NASDAQ:ARAV - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two...\n more…
VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St VYNE Therapeutics ( NASDAQ:VYNE ) Second Quarter 2024 Results Key Financial Results Net loss: US$9.40m (loss narrowed...\n more…
VYNE Therapeutics (NASDAQ:VYNE) Rating Reiterated by HC Wainwright
Ticker Report VYNE Therapeutics (NASDAQ:VYNE - Get Free Report)s stock had its "buy" rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga...\n more…
VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nVYNE stock results show that VYNE Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second...\n more…
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $3.08 per share a year ago. These...\n more…